Wearable Technology for Remote Monitoring of Disease Symptoms and Fatigue in Myasthenia Gravis


Topic:

Other

Poster Number: P363

Author(s):

Ram Kinker Mishra, PhD, BioSensics, Newton MA, İlkay Yıldız Potter, PhD, Biosensics LLC, Adonay Nunes Sastre, PhD, BioSensics, Newton MA, Meghan McAnally, MD, MPH, Neuromuscular and Neurogenetic Disorders of Childhood Section, NIH, Carsten G Bönnemann, National Institute of Neurological Disorders and Stroke, Petra Duda, MD, PhD, UCB, Cambridge, MA, USA ( at the time of the study), Ashkan Vaziri, PhD, Biosensics LLC, Amanda Guidon, MD, Massachusetts General Hospital, Harvard Medical School

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness and fatigue. Traditional clinical assessments can be too infrequent to capture the day-to-day variability of MG symptoms and susceptible to variability in operator and participant performance that can impact their sensitivity and clinical meaningfulness. Wearable sensors can provide a more precise, frequent, and quantitative tool for assessing disease symptoms in MG and other neurological disorders. Twenty individuals diagnosed with MG (mean age 59.2 ± 16.2 years) were monitored at home for seven consecutive days using the PAMSys pendant sensor, which tracks physical activity and posture. 19 of the 20 subjects achieved 100% compliance, wearing the sensor continuously around the clock (24 hours a day, 7 days a week). A correlation analysis between sensor-derived measures and standard questionnaires and clinical assessments, including MG activities of daily living profile (MG-ADL), MG composite scale (MGC), and Neuro-QOL Fatigue was performed. The results demonstrated significant correlations between physical activity metrics and clinical outcomes, highlighting the potential of wearable sensors to provide continuous, objective, and real-world data on disease manifestation. Stepwise linear regression analysis identified total standing time and total walking bouts as significantly correlated with patient-reported outcomes and clinical scores, including MG-ADL and QOL. In conclusion, our study establishes the feasibility and initial clinical validity of using wearable sensors for monitoring disease severity and fatigue in MG.